Wednesday 24 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Optibiotix - launch of Slimbiome and LPLDL products. Read closely & buy

By HotStockRockets | Wednesday 17 May 2017

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

OptiBiotix Health (OPTI) has announced what it terms the "successful" launch of its SlimBiome® and LPLDL® products at the Vitafoods Europe tradeshow in Geneva from the 9-11 of May 2017. The event provided the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. This is viewed as one of the world's leading trade fairs for the food and drinks industry. Yadda, yadda, yadda. Companies always say launches are successful. More jam tomorrow. So what. Etc. But no read on... We have underlined a few key words for you.

OptiBiotix launched the first of its range of heart health products containing LPLDL® called CholBiome and CardioBiome, and its SlimBiome® weight management technology. Both product types were exhibited in the New Products Zone and at Sacco's and Nutrilinea's stands. Sacco and Nutrilinea are OptiBiotix's European manufacturing and formulation partners and have an extensive European network to maximise the commercial opportunity provided by these products. Both LPLDL® and SlimBiome® were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia, Australia and the USA.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in selling our products. This has already resulted in some companies sending through draft contracts. The Company anticipates that this interest will start to generate revenues from both ingredient supply, and as a component in high value white label and branded formulations and presentations, across multiples territories. We are at the start of the commercialisation process but are really excited at the high level of interest in our products. We look forward to building commercial partnerships, market presence, and multiple revenue streams in both consumer health and pharmaceutical markets around the world."


You read that. Less than a week after the show contracts are coming in for discussion. They will be signed and numerous revenue streams will then start to flow. Optibiotix is very real and this is the start of an ARM-style ramp up you can only get with IP companies as we explained when urging you to buy at 62p a few days ago. The shares are a tad ahead on this news at 67p-70p as the market seems to have missed its import. The stance is STRONG BUY at up to 80p with a target to sell of well over 100p very soon.

This article first appeared on HotStockRockets, where two emergency share tips were published last week. For those, and to catch the next red hot share tips from the HotStockRockets team out shortly, for just £5 click HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI


Comments are turned off for this article.

Site by Everywhen